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Abstract
Methionine adenosyltransferases MAT I and MAT III (encoded byMat1a) catalyze S-adeno-
sylmethionine synthesis in normal liver. Major hepatic diseases concur with reduced levels
of this essential methyl donor, which are primarily due to an expression switch fromMat1a
towardsMat2a. Additional changes in the association state and even in subcellular localiza-
tion of these isoenzymes are also detected. All these alterations result in a reduced content
of the moderate (MAT I) and high Vmax (MAT III) isoenzymes, whereas the low Vmax (MAT
II) isoenzyme increases and nuclear accumulation of MAT I is observed. These changes
derive in a reduced availability of cytoplasmic S-adenosylmethionine, together with an effort
to meet its needs in the nucleus of damaged cells, rendering enhanced levels of certain epi-
genetic modifications. In this context, the putative role of protein-protein interactions in the
control of S-adenosylmethionine synthesis has been scarcely studied. Using yeast two
hybrid and a rat liver library we identified PDRG1 as an interaction target for MATα1 (cata-
lytic subunit of MAT I and MAT III), further confirmation being obtained by immunoprecipita-
tion and pull-down assays. Nuclear MATα interacts physically and functionally with the
PDRG1 oncogene, resulting in reduced DNA methylation levels. Increased Pdrg1 expres-
sion is detected in acute liver injury and hepatoma cells, together with decreasedMat1a
expression and nuclear accumulation of MATα1. Silencing of Pdrg1 expression in hepa-
toma cells alters their steady-state expression profile on microarrays, downregulating
genes associated with tumor progression according to GO pathway analysis. Altogether,
the results unveil the role of PDRG1 in the control of the nuclear methylation status through
methionine adenosyltransferase binding and its putative collaboration in the progression of
hepatic diseases.
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Introduction
Transmethylations encompass a large variety of reactions in which a methyl group is incorpo-
rated into a diversity of substrates, including DNA, proteins and small molecules [1, 2]. These
processes require methyl donors, a role performed mainly by S-adenosylmethionine (Ado-
Met) in mammals [3, 4]. Synthesis of this metabolite is carried out by addition of the adeno-
sine moiety of ATP to the methionine sulfur atom in a particular two-step reaction (requiring
Mg2+ and K+ ions) catalyzed by methionine adenosyltransferases (MATs)[3]. Three MAT
genes exist in mammals (Mat1a,Mat2a andMat2b), which encode for two catalytic subunits
(MATα1 and MATα2) and a regulatory β-subunit (MATβ)[3, 5].Mat1a achieves its highest
expression levels in normal liver, although small levels can be detected in almost every tissue
[6]. In contrast,Mat2a is preferentially expressed in extrahepatic tissues and in fetal liver, a
pattern also followed byMat2b [3, 4, 7, 8]. Rat MATα1 and MATα2 are 85% identical at the
amino acid level, reflecting the high conservation detected among α-subunits in the MAT
family [9]. MATβ is an unrelated protein classified into the PFAM 04321 family of oxidore-
ductases [3], which regulates the activity of MATα2 oligomers by enhancing their affinity for
methionine (reviewed in [3, 4]). These subunits associate to constitute three isoenzymes: the
homo-oligomers MAT I and MAT III, a tetramer and a dimer of MATα1 subunits, respec-
tively [3]; and the hetero-trimer MAT II composed by a MATα2 dimer and one MATβ sub-
unit [10]. Structural studies have demonstrated that the minimum active assembly is a dimer
of α-subunits, with both monomers contributing residues to form two active sites at their
interface [4, 11–13].
Most of the hepatic diseases studied to date, including cirrhosis, hepatocellular carcinoma
or acute liver injury, concur with a reduction in AdoMet concentrations due to a decrease in
Mat1a expression and the concomitant increase in that ofMat2a andMat2b [3, 14, 15].
Effects at the cytosolic protein level follow the same trend with increases in MATα2 and
MATβ and a reduction in MATα1, which also changes its preferred association state towards
MAT III [16, 17]. Data regarding the MAT nuclear pool are limited, due to their recent iden-
tification in this compartment [6, 18]. Nevertheless, a distinct regulation between cyto-
plasmic and nuclear levels of MATα1 is detected in rat models of acute liver injury, which
show nuclear accumulation of the protein together with its cytoplasmic reduction [17].
Nuclear MAT activity rises together with MAT I content as compared to normal liver, and
correlates with increased levels of histone 3 K27 trimethylation (me3K27H3), an epigenetic
methylation involved in gene repression [17, 19]. Additional effects derive from the fact that
most of these diseases also present with oxidative stress, and hence with enhanced production
of free radicals, nitric oxide and/or changes in the GSH/GSSG ratio. These outcomes result
in post-translational modifications reducing MAT I/III activity and/or alterations in the
association state [20–23]. MATα2 is protected against these post-translational modifications
by the lack of equivalent residues in its sequence [24, 25], but its oligomerization with MATβ
is favored by the enhancement of NADP+ levels, hence aiding to reduce AdoMet production
[10, 25].
In this context, data about the role of protein-protein interactions in MAT regulation are
limited to a few studies concentrated on MATα2 and MATβ, especially in cancer cells [18,
26–28]. Altogether these results show an evident lack of information regarding putative
MATα1 interactions, and hence, we have addressed this aspect searching for liver proteins
able to interact with MATα1 using yeast two-hybrid screening. This approach rendered the
identification of the PDRG1 oncogene as a novel interaction partner for MATα1 in the
nucleus of hepatic cells.
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Materials and Methods
Plasmids and mutagenesis
The ORF of ratMat1a was obtained by NdeI/BamHI digestion of pSSRL-Blue T2 [29], and
cloned into pGBKT7 (Clontech, Mountain View, CA, USA) to get pGBKT7-MAT1A. Cloning
into the NcoI/BamHI sites of pACT2 (Clontech) required three steps: i) amplification of the
Mat1a ORF from pSSRL-Blue T2 using the primers: 5’-AACATACCATGGAGATGAATGGACC
TGTGGATG-3’(sense; NcoI site underlined) and 5’-AGGGAACAAAAGCTGGAGC-3’
(reverse); ii) NcoI/BamHI digestion of the amplified fragment that renders the ORF in two
fragments; and iii), sequential cloning of the two fragments into pACT2 to obtain
pACT2-MAT1A.
One of the pACT2 plasmids containing the full ORF of rat Pdrg1 (402 bp) was used for
amplification with the primers 5’-CGGAATTCCTCTGTGGCACCATGGTGT-3’(sense; EcoRI
site underlined) and 5’-CGGGATCCTCATCCTTTCAAGATGACCTGG-3’(reverse; BamHI
site underlined). The amplification conditions included: i) 2 min denaturation at 95°C; ii) 30
cycles including 30s denaturation at 95°C, 1 min annealing at 56°C and 1 min extension at
72°C; and iii) 10 min extension at 72°C. The amplified fragment was cloned into pBluescript
SK+, rendering pBS-PDRG1. EcoRI/NotI digestion of pBS-PDRG1 allowed subcloning of the
insert into pHA(del), lacking C876 of pCMV-HA [17], and pGEX-5X-1 (GE Healthcare, Upp-
sala, Sweden) to produce pHA-PDRG1 and pGEX-PDRG1, respectively. The HA-tagged
PDRG1 contained 22 additional residues at the N-terminal (MYPYDVPDYALMAMEAEFLCGT;
HA-tag underlined), whereas the GST-PDRG1 construct included a 9 amino acid linker
(GIPEFLCGT) between the fused proteins. Cloning into pEGFP-N1 (BD Biosciences, San Jose,
CA, USA) required amplification of the Pdrg1 ORF from pACT2-PDRG1, as described above,
using the same sense primer and a new antisense primer to eliminate the stop codon (5’-
CGGGATCCCGTCCTTTCAAGATGACCTGGAG-3’). The amplified fragment was EcoRI/
BamHI digested and cloned into pEGFP-N1 (Clontech), rendering pPDRG1-EGFP. The corre-
sponding fused protein contains a 7 amino acid linker (RDPPVAT) between PDRG1 and
EGFP. A NdeI restriction site was included on pBS-PDRG1 using the QuikChange method
(Stratagene, La Jolla, CA, USA), the sense primer 5’-CTGTGGCACCATATGGTGTCCCCC
GAG-3’ and its complementary. NdeI/BamHI digestion of the modified pBS-PDRG1 allowed
subcloning of the insert into pT7.7 (Dr. Stan Tabor, Harvard Medical School, Boston, MA,
USA) to obtain pT7.7-PDRG1. The ORF of rat Pdrg1 was extracted from pT7.7-PDRG1 by
NdeI/PstI digestion and subcloned into pTYB12 (New England Biolabs, Beverly, MA, USA) to
obtain pTYB12-PDRG1.
PDRG1 deletion mutants were generated at the N-terminal (ΔN), C-terminal (ΔC) and both
ends (ΔNC). For this purpose, amplification from pBS-PDRG1 using the primers 5’-
GGAATTCATGGACAAGCGGCAGATTGTAGACC-3’(sense; EcoRI site underlined) and 5’-
ATAAGAATCGGCCGCTCTAGAACTAGTGGATCC-3’(reverse; NotI site underlined) was car-
ried out, to obtain an ORF lacking bases 4–75 of the N-terminal. The amplified fragment was
digested and cloned into the EcoRI/NotI sites of pGEX-5X-1, to obtain pGEX-ΔN-PDRG1.
Plasmids pGEX-PDRG1 and pGEX-ΔN-PDRG1 were used to include a new stop codon at
position 321–323 by the QuikChange method, the primer 5’-CTCCTAGAAGCCCAATGA
AAACCGGAGCTAAAGG-3’and its complementary, rendering pGEX-ΔC-PDRG1 and pGEX-
ΔNC-PDRG1, respectively.
Additional plasmids used in this work include: pFLAG-MAT and pSSRL-T7N containing
the ratMat1a ORF [6, 30]; pT7.7-MAT2A including the humanMAT2A ORF [10];
pT7.7-MAT2B containing the humanMAT2BORF [10]; and pTYB12-MAT2B that was gener-
ated by NdeI/EcoRI digestion of pT7.7-MAT2B and cloning of the insert into pTYB12. Human
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MATα2 and MATβ subunits are 98% and 95% identical to their rat homologues. The presence
of the correct sequences in all the plasmids described above was verified by automatic sequenc-
ing at the Genomic Service of the Instituto de Investigaciones Biomédicas “Alberto Sols”
(IIBM, CSIC-UAM).
Yeast two hybrid
A rat liver Matchmaker cDNA library (RL4004AH; Clontech) and the AH109 yeast strain were
used for screening in search for MATα1 interactions. Yeast transformations were carried out
using EasyComp solutions (Invitrogen, Carlsbad, CA, USA) and the resulting transformants
grown in low (-Leu/-Trp; -LW) and high stringency (–Ade/-His/-Leu/-Trp; -AHLW) SC
media for selection. Screening of 6.5 x105 clones was carried out and 41 putative interactions
detected, from which only 23 were confirmed in–AHLW SC medium. DNAs of the positive
clones were isolated and used to transform E. coli DH5α competent cells. Plasmids were puri-
fied using Qiagen plasmid purification kits (Qiagen, Hilden, Germany) and sequenced. Eight
biologically relevant preys were found, the rest corresponding to MATα1-MATα1 interactions;
this large background was expected for a homo-oligomeric protein and guarantees native
MATα1 folding of the fusion proteins. Verification of positive interactions was performed by
cotransformation of plasmids harboringMat1a ORF and putative preys, followed by growth
on–AHLW SC media.
Cell culture, transfections and confocal microscopy
Commercial CHO (chinese hamster ovary), COS-7 (monkey kidney), H35 (rat hepatoma),
N2a (mouse neuroblastoma) and HEK-293T (human kidney) cell lines were obtained from the
ATCC and IIBM collections and grown in DMEM (Gibco, Grand Island, NY, USA) supple-
mented with 10% (v/v) fetal bovine serum and 2 mM glutamine. Transient transfections with
pHA-PDRG1, pPDRG1-EGFP or pFLAG-MAT were carried out for 48 hours using lipofecta-
mine (Invitrogen), as previously described [6]. Experiments requiring cotransfection included
pHA-PDRG1 or pPDRG1-EGFP and pFLAG-MAT.
Direct fluorescence observation (40000–100000 cells) and immunofluorescence (10000–
40000 cells) were carried out with transiently transfected cells grown on glass coverslips as pre-
viously described [6]. Nuclei were stained using 5 μg/ml Hoechst 33342 dye (Molecular Probes,
Eugene, OR, USA) for 1 hour before direct observation or fixation. Minor modifications con-
cerned the use of 5 min fixation and permeabilization steps. The antibodies and dilution used
for immunofluorescence are listed in Table 1. Glass coverslips were mounted using Prolong
(Molecular Probes). Cell imaging (0.3–0.4 μm sections) was performed on a Leica TCS SPII
Spectral microscope using a 63x /1.3 NA objective. Images were analyzed using the Leica Con-
focal Software (LCS Lite, Zurich, Switzerland).
Subcellular fractionation and immunoprecipitation
Total lysates were prepared from 2 x 106 cells in 200 μl of 50 mM Tris/HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% (v/v) NP-40, 1 mMDTT containing protease inhibitors (1 mM PMSF,
1 mM benzamidine, 2 μg/ml aprotinin, 1 μg/ml pepstatin A, 0.5 μg/ml leupeptin, 2.5 μg/ml
antipain), after 10 min incubation on ice, by a 6-fold passage through a needle. Input samples
(50 μl) were taken at this step and the remaining sample centrifuged for 15 min at 10000 xg at
4°C. When subcellular fractionation was required either from liver or cells, nuclear and cyto-
plasmic fractions were prepared as previously described [6]. For anti-HA immunoprecipita-
tion, total lysates (150 μl), nuclear (100 μl) or cytosolic fractions (100 μl) were precleared using
anti-mouse IgG (2 μg) for 2 hours at 4°C and centrifuged for 15 min at 10000 xg. The
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supernantants were incubated overnight with anti-HA (2 μg) coupled to protein A Sepharose
CL-4B (GE Healthcare) at 4°C. Anti-FLAG immunoprecipitation was carried out overnight at
4°C by incubation of the subcellular fractions with anti-FLAGM2 Affinity Gel (50 μl; Sigma,
Madrid, Spain; A2220). The beads were washed 3 times and boiled in Laemmli sample buffer
(40 μl) containing 100 mMDTT for 10 min. Samples were centrifuged for 1 min at 10000 xg,
the supernatants loaded on SDS-PAGE gels and proteins were transferred to nitrocellulose
membranes for western blotting.
Western blotting
Immunoblotting was carried out as described previously [29] using the antibodies and condi-
tions listed in Table 1. For FLAG-MATα1 detection, after anti-HA immunoprecipitation,
mouse TrueBlot ULTRA (1:1000 v/v; eBioscience, San Diego, CA, USA; 18–8817) was used.
Protein bands were visualized using Western Lightning™ chemiluminescence reagent (Perkin
Elmer, Waltham, MA, USA).
Analytical gel filtration chromatography
HEK 293-T cells (4 x 106) transiently transfected with the plasmids of interest were used to
obtain the nuclear fractions as previously described [6]. Samples (100 μl) of the nuclear frac-
tions were injected on a Superose 12 10/300 GL column (GE Healthcare), and elution per-
formed as previously described [23]. Dot-Blot analysis of the fractions (100 μl) was performed
using the same conditions than for western blot. The protein standards (GE Healthcare and
Sigma) used were: Blue dextran (2000 kDa); ferritin (440 kDa); β-amylase (200 kDa); aldolase
(150 kDa); alcohol dehydrogenase (150 kDa); conalbumin (75 kDa); ovalbumin (43 kDa); car-
bonic anhydrase (29 kDa); lysozyme (14.4 kDa); and ATP (551 Da).
Table 1. Antibodies used in this work.
Primary antibody (Source) Dilution (v/v)1 Secondary antibody Dilution (v/v) Application2
Rabbit anti-MATα1 (Mingorance et al. [29]) 1:10000 Goat anti-rabbit IgG (BioRad; 170–6515) 1:10000 WB
Rabbit anti-MATα1 (Mingorance et al. [29]) 1:1000 Goat anti-rabbit Alexa Fluor 546 (Molecular Probes; A11035) 1:400 IF
Rabbit anti-MATβ (Abcam; ab109484) 1:2000 Goat anti-rabbit IgG (BioRad; 170–6515) 1:10000 WB
Mouse anti-FLAG (Sigma; F3165) 5 μg/ml Anti-mouse IgG (GE Healthcare; NA931) 1:20000 WB
Mouse anti-FLAG (Sigma; F3165) 5 μg/ml Goat anti-mouse Alexa Fluor 488 (Molecular Probes;
A11029)
1:400 IF
Mouse anti-TBP (Santa Cruz; sc-56796) 1:1000 Anti-mouse IgG (GE Healthcare; NA931) 1:20000 WB
mouse anti-tubulin (Sigma; T9026) 1:2500 Anti-mouse IgG (GE Healthcare; NA931) 1:20000 WB
Mouse anti-HA (Covance; MMS-101R) 1:1000 Anti-mouse IgG (GE Healthcare; NA931) 1:20000 WB
Mouse anti-HA (Covance; MMS-101R) 1:1000 Goat anti-mouse Alexa Fluor 488 (Molecular Probes;
A11029)
1:400 IF
Mouse anti-GST (Cell Signaling; #2624) 1:10000 Anti-mouse IgG (GE Healthcare; NA931) 1:20000 WB
Mouse anti-SC35 (BD PharMingen;
556363)
1:1000 Goat anti-mouse Alexa Fluor 546 (Molecular Probes;
A11030)
1:400 IF
Chicken anti-MATα2 (Abcam; ab26174) 1:10000 Goat anti-chicken IgY (Abcam; ab6877) 1:2000 WB
Rat anti-HA (Roche; 11-867-423-001) 100 ng/ml Goat anti-rat Alexa Fluor 488 (Molecular Probes; A11006) 1:500 IF
Rabbit anti-PDRG1 (Abcam; ab121219) 1:1000 Goat anti-rabbit IgG (BioRad; 170–6515) 1:1000 WB3
1Dilution expressed as (v/v), except where otherwise indicated
2WB, western blotting; IF, immunoﬂuorescence.
3Exposed on ultrasensitive ﬁlm.
doi:10.1371/journal.pone.0161672.t001
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Production of recombinant proteins
The recombinant proteins used in this study were overexpressed in E. coli BL21(DE3) Codon
Plus cells using the specific conditions described in Table 2. Refolding and purification of
recombinant MATα1 and MATα2 from inclusion bodies was carried out as previously
described [10, 30]. Purification of MATβ and PDRG1 was performed using soluble fractions
and chitin beads (New England Biolabs) as previously described for betaine homocysteine
methyltransferase [31], but using 50 mM β-mercaptoethanol for 60 hours at room temperature
(23°C) for tag excision. Purification of GST-PDRG1 was carried out using Glutathione-Sephar-
ose 4B (GE Healthcare) following manufacturer's instructions and the protein was eluted with
20 mMGSH. This tagged-PDRG1 was preferred when detection by western blotting or dot-
blot was required. MAT II (α22β) was produced by incubation of equimolar concentrations of
both recombinant subunits for 1 hour at 4°C, as described by González et al. [10]. Similarly,
oligomers containing MATα1 or MATα2 and GST-PDRG1 were obtained by incubation of
equimolar concentrations of the purified recombinant proteins for 1 hour at 4°C, followed by
gel filtration chromatography on Biogel A columns (1.5 x 90 cm; Bio-Rad, Hercules, CA,
USA), equilibrated and run with 50 mM Tris/HCl pH = 8, 10 mMMgSO4, 50 mM KCl at 10
ml/h and 4°C. A280 was detected during elution and MAT activity was measured in the col-
lected fractions (3 ml). Samples (1 ml) of each fraction were precipitated with TCA and loaded
onto SDS-PAGE gels, where the presence of both proteins was detected after Coomasie blue
staining and/or western blotting of the pooled activity peaks. The protein standards (GE
Healthcare and Sigma) used were: Blue dextran (2000 kDa); ferritin (440 kDa); aldolase (150
kDa); conalbumin (75 kDa); ovalbumin (43 kDa); and ATP (551 Da).
Pull-down
Bacterial pellets overexpressing the protein of interest were lysed by sonication (5 cycles of 30s
on/off) in 1:5 (w/v) PBS buffer containing 300 mMNaCl, 10 mM DTT and protease inhibitors.
Soluble fractions were isolated by centrifugation for 30 minutes at 100000 xg at 4°C. Aliquots
(30 μl) of Glutathione-Sepharose (GE Healthcare) were equilibrated in lysis buffer and incu-
bated with extracts (1 mg total protein) overexpressing GST, GST-PDRG1 or the truncated
forms for 1 hour at 4°C. The gel samples were washed three times with cold PBS by centrifuga-
tion at 3500 xg for 5 min at 4°C before addition of GST overexpressing extracts (5 mg), alone
Table 2. Conditions for the expression of recombinant proteins.
Induction1
plasmid DO600 Time (h)
2 Temperature (°C)
pGEX-5X-1 0.3–0.4 20 20
pGEX-PDRG1 0.3–0.4 6 20
pGEX-ΔN-PDRG1 0.3–0.4 9 20
pGEX-ΔC-PDRG1 0.3–0.4 9 20
pGEX-ΔNC-PDRG1 0.3–0.4 6 20
pSSRL-T7N 0.3–0.4 3 37
pT7.7-MAT2A 0.3–0.4 20 27
pTYB12-MAT2B 0.5–0.6 4 20
pTYB12-PDRG1 0.5–0.6 20 20
1 Induction with IPTG (0.5 mM ﬁnal concentration) when the desired D.O. at 600 nm was achieved
2 Cultures were continued for the time length and temperature speciﬁed.
doi:10.1371/journal.pone.0161672.t002
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or in combination with those containing the MAT proteins of interest (500 μg), to avoid unspe-
cific binding. Parallel experiments were also carried out using purified MATα2, MATβ or
MAT II proteins (100 μg). The mixtures were incubated with the gel for one additional hour at
4°C, and after extensive washing, the gel was boiled in Laemmli buffer. The bound proteins
were loaded into SDS-PAGE gels and electrotransferred for western blotting.
Animal models and cell treatment
Male Wistar rats (200 g) were subjected to acute D-galactosamine intoxication for 48 hours and
control and treated livers extracted, as described previously [17]. Additionally, liver samples of
9-week old Long Evans Cinnamon (LEC) and control Long Evans (LE) rats were also used [32].
All animals received standard diets ad libitum and were sacrificed using CO2 asphyxiation. The
experiments included in this study were approved by the CSIC Bioethics Committee and carried
out in full accordance with Spanish regulations (RD 53/2013) and the European Community
guidelines (2010/63/EU) for the use of laboratory animals. Tissue extraction and preservation
was carried out as described [17, 32]. Effects on Pdrg1mRNA half-life were analyzed by
RTqPCR using control and 10 mMD-galactosamine-treated H35 cells (3 x 105), in the presence
or absence of 5 μg/ml actinomycin D (Sigma), as previously described [17].
RNA isolation and real-time RT-PCR
RNA purification and analysis was carried out as previously described using 100–150 mg of rat
tissues or H35 cells (4 x 105 cells)[6, 32]. Gene specific primers for rat Pdrg1 were designed using
the program Primer Express 3.0 (Applied Biosystems, Foster City, CA, USA) with Tm values
between 58–60°C (sense 5’-GACCTGGACACCAAGAGGAA-3’, antisense 5’-GGTGCTCCT
GATCTTTCTGG-3’);Mat1a and 18s primers were previously described [32]. Reverse transcrip-
tion and cDNA amplification were carried out as described [32], using 300 nM (Mat1a and
Pdrg1) and 100 nM (18s) primer concentrations and Power SYBR Green PCRMaster Mix
(Applied Biosystems). Expression was evaluated using the ABI 7900HT Real-Time PCR system
(Applied Biosystems) at the Genomic Service of our institute. Relative expression ratios were nor-
malized to the geometric mean of the 18s gene used as a control. Experimental efficiencies were
calculated for each transcript and used to obtain the fold changes according to Pfaffl et al. [33].
DNAmethylation measurements
Genomic DNA was isolated from transiently transfected CHO cells (5 x 105 cells) using the
DNeasy kit (Qiagen) and the incorporation of methyl groups from [3H-methyl]-AdoMet (GE
Healthcare) was followed by the inverse radioactivity assay described by Christman et al. [34]
using E. coli SssI methylase (New England Biolabs).
Silencing of Pdrg1 expression in H35 cells and production of stable
clones
Reduction of rat Pdrg1 expression was carried out by transfection of H35 cells (4 x 105 cells) with
SureSilencing shRNA plasmids (SaBioscience, IZASA, Madrid, Spain) containing sequences
designed for this purpose (GGAGCACCTGGATAAAGAAAT, shRNA1; TCACCTTAAGACGAAGG
AAAT, shRNA2; ACCTTAAGACGAAGGAAATGA, shRNA3; AGGAGCACCTGGATAAAGAAA,
shRNA4) and a negative control sequence (GGAATCTCATTCGATGCATAC, CN). For initial eval-
uation of the silencing ability of each plasmid, transfections were carried out in triplicate for 48
hours, followed by enrichment of the transfected population with 1.8 mg/ml G418 (Gibco) for
two weeks. RNA was extracted from half of the population and used for RTqPCR evaluation of
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Pdrg1 expression. Only cells harboring plasmids inducing more than 70% reduction of Pdrg1
expression at this point were used for further selection (S1 Fig). Stable clones for the negative
control, shRNA3 and shRNA4 plasmids were finally obtained using 4 mg/ml G418 for two addi-
tional weeks. Approximately 200 stable clones for each plasmid were isolated and analyzed
RTqPCR and one clone of each, the negative control (CN-10), shRNA3 (3–44) and shRNA4 (4–
18), exhibiting reproducible behavior were selected for further experiments.
Differential expression profile and microarray analysis
Four biological replicates of stable clones (CN-10, 3–44, 4–18) and a transiently transfected
shRNA3 H35 enriched pool (shRNA3T), were independently hybridized for each transcrip-
tomic comparison. Total RNA (200 ng) was amplified using One Color Low Input Quick Amp
Labeling kit (Agilent Technologies, Santa Clara, CA USA) and purified with RNeasy Mini kit
(Qiagen). Preparation of probes and hybridization was performed as described in the One-
color Microarray Based Gene Expression Manual v6.5 (Agilent Technologies), using Rat Gene
Expression Microarray v3 Agilent 4x44K. Briefly, for each hybridization 600 ng of Cy3 probes
were mixed and added to 10x Blocking Agent (5 μl), 25x Fragmentation Buffer (1 μl) and
Nuclease free water in a 25 μl reaction, incubated at 60°C for 30 minutes to fragment RNA and
stopped with 2x Hybridization Buffer (25 μl). Samples were placed on ice and immediately
loaded onto arrays, hybridized for 17 hours at 65°C and washed for 1 minute sequentially with
GE wash buffers 1 and 2 at room temperature. Arrays were dried by centrifugation, images cap-
tured with an Agilent Microarray Scanner and spots quantified using Feature Extraction Soft-
ware (Agilent Technologies). Background correction and normalization of expression data
were performed using LIMMA [35, 36]. Linear model methods were used to determine differ-
entially expressed genes. Each probe was tested for changes in expression over replicates by
using an empirical Bayes moderated t-statistic [35]. Control of false discovery rate was achieved
by correction of p-values as previously described [37]. The expected false discovery rate was
controlled to be less than 5%. Hybridizations and statistical analysis were performed at the
Genomics Facility of the Centro Nacional de Biotecnología (CNB-CSIC). FIESTA Viewer v1.0
was used to identify 114 genes exhibiting changes2-fold with FDR<0.05, clustering and
Heatmaps were prepared using Cluster [38] and Java TreeView [39], whereas pathway analysis
was carried out with BioProfiling [40]. Verification of expression changes was carried out by
RTqPCR for selected genes using RNA samples of stable clones and appropriate TaqMan
probes (Table 3). Microarray results have been deposited in the GEO Database and are accessi-
ble through the series accession number GSE69337 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE69337).
Table 3. Data of TaqMan probes.
gene reference Overlapping exons
Aacs Rn00675033_ml 16–17
Acadm Rn00566390_ml 2–3
Adm Rn01507680_gl 3–4
Aldob Rn01768292_ml 8–9
Hmgcs2 Rn00597339_ml 5–6
Lipc Rn01530834_ml 1–2
Mat1a Rn00563454_ml 1–2
Mat2a Rn01643368_gl 1–2
Pdrg1 Rn01535663_ml 3–4
Sstr2 Rn01464950_gl 1–2
doi:10.1371/journal.pone.0161672.t003
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Growth curves
Eight replicas per experiment of each, H35 cells and stable clones (CN-10 and 4–18), were
seeded (10000 cells/well) and grown for up to 8 days using the standard medium. At the
desired time points the cell number was measured using crystal violet by the procedure of Gil-
lies et al., as previously described [41, 42]. Briefly, wells were washed with PBS, cells fixed using
1% (v/v) glutaraldehyde (Fluka, Madrid, Spain) for 15 minutes and stained using 0.1% (w/v)
crystal violet (Merck, Darmstadt, Germany) for 30 minutes. Following extensive washing, cells
were allowed to dry for 24 hours, the color was solubilized with 10% (v/v) acetic acid (Merck)
and the A590 measured.
PDRG1 structural model
The rat PDRG1 sequence and the online Protein Homology/analogY Recognition Engine
(PHYRE; http://www.sbg.bio.ic.ac.uk/~phyre/) were used to generate a structural model, which
includes residues 27–106 of the protein. This information was employed for the design of
PDRG1 truncated forms. Figures were prepared using PyMol (DeLano Scientific LLC, San Car-
los, CA, USA).
Determinations of enzymatic activities and protein concentrations
MAT activity was measured in column fractions (100–160 μl) of the different purification steps
as previously described [23]. Additionally, this same activity was evaluated in the pooled peaks
containing purified MATα1/GST-PDRG1 or MATα2/GST-PDRG1 complexes (160 μl). Assays
including PDRG1 or histone II A (Sigma) were carried out after preincubation on ice for 5
minutes with either purified recombinant MATα1, MATα2 or MAT II oligomers (0.7 μM),
using subunit molar ratios between 1:0 and 1:8 MATα/PDRG1 (160 μl) in a final reaction vol-
ume of 250 μl. LDH activity was determined spectrophotometrically in both cytosolic and
nuclear fractions as previously described [6]. Protein concentrations were measured using the
Bio-Rad protein assay kit (Bio-Rad) and bovine serum albumin as standard.
Statistical analysis
GraphPad Prism v. 5.0 (GraphPad Software, La Jolla, CA, USA) was used for statistical analysis
of the data, unless otherwise specified. Student’s t-test was preferred for analysis of experiments
containing two groups, whereas one-way ANOVA with Bonferroni post-hoc test was utilized
for multiple comparisons; differences were considered significant when p0.05.
Results
PDRG1 interacts with methionine adenosyltransferase α1
In order to identify proteins that interact with MATα1 a yeast two-hybrid screening was per-
formed using a rat liver cDNA library and the full-length ORF of ratMat1a as bait. Only one
prey was further confirmed using high stringency conditions, its sequence corresponding to
p53 and DNA damage-regulated gene 1 (Pdrg1; NM_001014762)(Fig 1A). Additional valida-
tion of the interaction was obtained using total lysates of CHO and HEK-293T cells transiently
cotransfected with both pFLAG-MAT and pHA-PDRG1. Immunoprecipitation with anti-
FLAG followed by western blotting using anti-HA revealed a band showing the expected size
for the HA-PDRG1 fusion protein (155 amino acids; 17.9 kDa) only in cotransfected cells (Fig
1B). The inverse immunoprecipitation was also carried out using anti-HA followed by western
blotting utilizing anti-FLAG and mouse TrueBlot ULTRA, to avoid hindrance of the FLAG--
MATα1 band by the immunoglobulin heavy chains. Anti-FLAG detected an unspecific band
PDRG1 Binds to Nuclear Methionine Adenosyltransferases
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Fig 1. PDRG1 interacts with methionine adenosyltransferase α1. (A)Growth of yeast cotransfectants harboring
pGBKT7-MATα1 (bait) and pACT2 plasmids (prey) including ORFs of MATα1, PDRG1, clone M2, clone M6 or
laminin (negative control) in low (-LW) and high (-AHLW) stringency SCmedia. Additional controls including the
empty pGBK plasmid are shown on the right. (B) Representative anti-FLAG immunoprecipitation results from four
independent experiments using total lysates of CHO cells transiently cotransfected with pFLAG-MAT and
pHA-PDRG1 or the empty plasmids (mock). The size of the standards is indicated on the left side of the panel. (C)
Representative anti-HA immunoprecipitation data from three independent experiments utilizing total lysates of HEK
293T cells transiently cotransfected with pFLAG-MAT and pHA-PDRG1 or the empty plasmids (mock). Western
blots of the input fractions were developed using anti-FLAG and anti-HA, whereas immunoprecipitates were
analyzed using anti-HA or anti-FLAGwith mouse TrueBlot ULTRA, as required. The arrow indicates an unspecific
band recognized by anti-FLAG slightly over the FLAG-MATα1 signal in HEK 293T samples. The size of the
standards is indicated on the left side of the panel. (D) Pull-down confirmation of the interaction using glutathione
Sepharose beads loaded with GST or GST-PDRG1 and incubated with recombinant MATα1 plus excess GST.
Results shown correspond to a typical experiments out of the five carried out; input fractions of the recombinant
proteins used (left) and pull-down results (right) are shown. The size of the standards is indicated on the left side of
the panel.
doi:10.1371/journal.pone.0161672.g001
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with slightly slower mobility than FLAG-MATα1 in all the immunoprecipitates, whereas only
cotransfected cells exhibited a band of ~50 kDa as expected for the FLAG-MATα1 protein (Fig
1C). Additionally, pull-down experiments were performed using glutathione Sepharose beads
loaded with GST (~25 kDa) or GST-PDRG1 (~41 kDa) and E. coli extracts overexpressing
MATα1. The presence of MATα1 among the proteins retained onto GST-PDRG1 beads was
confirmed by western blotting using anti-MATα1 (Fig 1D).
Interaction of MATα1 and PDRG1 involves the core structure of this
protein
There is no available structural information about PDRG1 that could serve to get insight into
the interaction domain. Using the PHYRE online engine, prefoldin was identified as the closest
structural homologue for PDRG1 and this information aided to build a structural model com-
prising residues K27-Q106. The model excluded the N- and C-terminal ends of the protein,
and showed the PDRG1 core as two α-helixes linked by a loop (Fig 2A). Based on these data,
three truncated forms of GST-PDRG1 were generated lacking the N- or C-terminal ends or
both (Fig 2B). Pull-down assays were then used to assay their ability to interact with MATα1 in
comparison with GST-PDRG1 (Fig 2C). No significant change in binding was detected for the
Fig 2. Structural model of rat PDRG1 and interaction of PDRG1 truncated forms with MATα1. (A)
PDRG1 structural model comprising residues K27-Q106 obtained with PHYRE. (B) Schematic
representation of PDRG1 and the truncated forms prepared; the modeled area (white box) and deleted
sequences (crossed box) are indicated. (C) Representative western blots of pull-down experiments carried
out with recombinant truncated PDRG1 forms and MATα1 using anti-GST and anti-MATα1. Incubations with
MATα1 were carried out in the presence of excess GST to avoid unspecific binding. The size of the standards
is indicated on the left side of the panels. (D)Quantification of the MATα1/GST-PDRG1 signal ratio
(mean ± SEM) from seven independent pull-down experiments (*p0.05 vs GST-PDRG1).
doi:10.1371/journal.pone.0161672.g002
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mutant lacking the N-terminal (GST-ΔN-PDRG1), whereas removal of the C-terminal end
increased the amount of MATα1 bound to both GST-ΔC-PDRG1 and GST-ΔNC-PDRG1 pro-
teins (Fig 2D). These results suggested that binding with MATα1 occurs through the structural
core of PDRG1, in an area partially covered by its C-terminal end.
PDRG1 is a nucleocytoplasmic protein that interacts with MATα1 in the
nucleus
MATα1 is located mainly in the cytoplasm of hepatocytes, small amounts being detected in the
nucleus, which is its preferred location in extrahepatic tissues and hepatoma cells [6]. On the
other hand, PDRG1 was initially found as cytoplasmic aggregates using fixed NIH3T3 and
HCT116 cells, but later identified in nuclear interaction complexes in LNCaP prostate cells [43,
44]. These data suggested different subcellular localizations for PDRG1 according to the cell
type, which may differ from those of MATα1. Hence, we used confocal microscopy and the
EGFP- and HA-tagged proteins to analyze PDRG1 distribution in additional cell lines, including
hepatic cells (Fig 3). Both direct fluorescence and immunofluorescence showed the same subcel-
lular distribution pattern with nuclear and cytoplasmic PDRG1 localization in all the cell lines
Fig 3. Subcellular localization of PDRG1 in mammalian cell lines. (A) Representative confocal
immunofluorescence images of HA-PDRG1 localization using mouse anti-HA and anti-mouse Alexa Fluor
488; a minimum of three independent experiments were carried out in cuadruplicate. CHO (Chinese hamster
ovary), COS-7 (monkey kidney), H35 (rat hepatoma) and N2a (mouse neuroblastoma) cells were transiently
transfected with pHA, pHA-PDRG1, pEGFP or pPDRG1-EGFP. (B) Representative results of direct
fluorescence localization using confocal microscopy of EGFP and PDRG1-EGFP; three independent
experiments were performed in duplicate. Both panels show colocalization with Hoechst nuclear staining in
white. (C) Histograms (mean ± SEM) show quantification results of nuclear (N) and cytoplasmic (C)
fluorescence signals of a minimum of 200 cells per condition, using the Leica confocal software. Results of
the C/N signal ratio calculated from immunofluorescence experiments are depicted. (D) Data of the C/N
signal ratio from direct fluorescence observations. Cells were classified as: C>N with a ratio above 1.2; C = N
when the ratio was 1 ± 0.2; and C<N with ratios below 0.8. Statistical evaluation was done by means of one-
way ANOVA with Bonferroni post-hoc (*p<0.05 vs C = N). Scale bar = 10 μm.
doi:10.1371/journal.pone.0161672.g003
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examined (Fig 3A and 3B). However, quantification of the fluorescence signals demonstrated
higher levels in the nucleus than in the cytoplasm in all the cases, except for N2a fixed cells (Fig
3C), and no statistical difference between PDRG1-EGFP and control EGFP distribution (Fig
3D). Confirmation of HA-PDRG1 localization to both subcellular compartments was also
obtained by subcellular fractionation of transiently transfected HEK 293T cells (Fig 4A).
Confocal microscopy also demonstrated HA-PDRG1 and FLAG-MATα1 colocalization in
both the cytoplasm and the nucleus in all cell types examined (Fig 4B). However, colocalization
is not synonymous of interaction, and hence transiently cotransfected COS-7 and HEK 293T
cells were used for subcellular fractionation and immunoprecipitation (Fig 4C). Western blots
of the nuclear and cytosolic input fractions showed expression of both HA-PDRG1 and
FLAG-MATα1, whereas only anti-FLAG immunoprecipitates from nuclear fractions exhibited
anti-HA signals with the expected HA-PDRG1 size (Fig 4C). These data suggested that the
interaction occurred in the nuclear compartment, where confocal microscopy also showed
Fig 4. Subcellular distribution of HA-PDRG1 and the HA-PDRG1/ MATα1 interaction. (A)
Representative western blots of nuclear (N) and cytoplasmic (C) fractions (50–70 μg) obtained from HEK
293T cells transiently transfected with pHA or pHA-PDRG1 in three independent experiments. Membranes
were analyzed using anti-HA, anti-TBP (nuclear marker) and anti-tubulin (cytoplasmic marker). (B)
Representative confocal immunofluorescence images (N = 50 per cell line) of CHO, COS-7, HEK 293T and
H35 cells transiently cotransfected with pHA-PDRG1 and pFLAG-MAT obtained using mouse anti-HA, rabbit
anti-MATα1 and the corresponding secondary antibodies coupled to Alexa Fluor 488 (green) or 546 (red).
Colocalization of both proteins is shown in yellow (scale bar = 12 μm) (C) Representative results of anti-FLAG
immunoprecipitations carried out in N and C fractions obtained from HEK 293T cells transiently cotransfected
with pFLAG-MAT and pHA-PDRG1 or the empty plasmids (mock). Input fractions were analyzed using anti-
FLAG, anti-HA, and antibodies against nuclear and cytoplasmic markers, whereas immunoprecipitates were
examined using anti-HA. Results correspond to a minimum of three independent experiments. (D)
Representative confocal immunofluorescence images of nuclear matrix preparations of HEK 293T and CHO
cells overexpressing HA-PDRG1 using rat anti-HA (green), mouse anti-SC-35 (red) and appropriate
secondary antibodies conjugated to Alexa Fluor dyes (N = 50 per cell line); colocalization appears in orange.
Scale bar = 12 μm.
doi:10.1371/journal.pone.0161672.g004
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HA-PDRG1 colocalization with the nuclear matrix marker SC-35 (Fig 4D), as previously
reported for MATα1.
PDRG1 interacts with MATα1 producing larger oligomers in nuclear
fractions
MATα1 subunits associate into homo-tetramers (MAT I) and homodimers (MAT III) in the
cytosol, whereas in the nucleus only MAT I and MATα1 monomers have been described [6,
17]. In order to explore whether PDRG1 displayed any preference for interaction with a spe-
cific MATα1 state, nuclear fractions from HEK 293T cells overexpressing HA-PDRG1, FLAG--
MATα1 or both were analyzed by analytical gel filtration chromatography (AGFC)(Fig 5).
Two elution peaks were detected for nuclear HA-PDRG1, one corresponding to a hexamer
(11.55 ml) and another as predicted for a monomer (14.28 ml)(Fig 5A). Elution of nuclear
FLAG-MATα1 occurred in the expected two peaks, corresponding to MAT I (10.71 ml) and
MATα1 monomers (13.02 ml)(Fig 5B). A mixed profile was detected in nuclear fractions of
cotransfected cells, as a result of the combination of peaks corresponding to HA-PDRG1 or
FLAG-MATα1 homo-oligomers, in addition to a new peak eluting at 10.08 ml (Fig 5C). Both
anti-HA and anti-FLAG antibodies detected this new peak, hence indicating the presence of
the two proteins in a larger association state with an estimated molecular mass of 360 kDa,
according to the elution profile of the standards.
Tissular expression of Pdrg1 andMat1a showed different patterns
The fact that PDRG1 immunoprecipitates with nuclear MATα1, suggested that this interaction
may be more relevant in extrahepatic tissues or in hepatic disease, two environments in which
MATα1 accumulates into this subcellular compartment [6, 17]. Therefore, we next examined
whether Pdrg1 expression followed the same trend thanMat1a using real-time RT-PCR
(RTqPCR). All the rat tissues examined showed Pdrg1 expression (Fig 6A), the highest levels
being detected in cerebellum and brain, whereas the lowest were found in liver and pancreas.
Surprisingly, this expression pattern was almost opposite to that exhibited byMat1a (Fig 6B)
and closer to the trend described forMat2a andMat2b.
We next examined hepatic Pdrg1 expression in two animal models of liver disease and in hep-
atoma cells. Livers of 9-week old LEC rats, a model of Wilson disease, exhibited a moderate
decrease inMat1a expression (~20%) that was not followed by changes in Pdrg1 expression as
compared to the controls (Fig 6C). In contrast, livers of D-galactosamine intoxication (a model
of acute liver injury) and H35 cells with strong reductions inMat1a expression (~70% and
>95%, respectively) exhibited 5- and 50-fold increases in Pdrg1mRNA levels, respectively, as
compared to normal liver (Fig 6D and 6E). Putative effects on Pdrg1mRNA stability were also
examined in H35 cells treated with D-galactosamine, where a trend towards increased half-life
was detected in cells treated with actinomycin D and the drug (18.49 ± 5.18 vs. 39.19 ± 12.11
hours, p = 0.087). Protein levels were examined in hepatic subcellular fractions of control and D-
galactosamine-treated rats using the available anti-PDRG1 antibodies. Given the low hepatic lev-
els of the protein and the very low affinity exhibited by the antibodies, only extensive exposure of
the membranes on ultrasensitive films showed a band of the expected size in the nuclear fractions
(S2 Fig). Densitometric scanning confirmed a 3-fold elevation of nuclear PDRG1 levels in D-
galactosamine intoxication. Thus, both proteins increase their nuclear levels in acute liver injury.
PDRG1 was also an interaction target for MATα2
The fact that Pdrg1 andMat2a share similar expression patterns, together with the high level of
identity between MATα1 and MATα2, prompted us to examine the possibility that PDRG1
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Fig 5. Evaluation of the PDRG1/ MATα1 association in nuclear extracts by analytical gel filtration
chromatography. (A) Elution profile of nuclear extracts overexpressing HA-PDRG1 obtained on a Superose
12 10/300 GL column and analyzed by dot-blot using anti-HA. (B) Elution profile of nuclear FLAG-MATα1
detected using anti-MATα1. (C) Elution profile of nuclear extracts overexpressing HA-PDRG1 and
FLAG-MATα1; the arrow indicates the new peak recognized by both antibodies (anti-HA (▲) and anti-MAT
(●)). Elution of the protein standards was as follows: blue dextran (7.4 ml); ferritin (9.82 ml); β-amylase (a;
10.62 ml); aldolase (11.1 ml); alcohol dehydrogenase (b; 11.34 ml); conalbumin (c; 12.78 ml); ovalbumin
(13.3 ml); carbonic anhydrase (14 ml); lysozyme (17.31 ml); and ATP (17.65 ml). The figure shows
representative profiles obtained in five independent experiments.
doi:10.1371/journal.pone.0161672.g005
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was also an interaction target for the later. The putative interaction was analyzed both in the
absence or presence of MATβ using the human MAT II subunits, which exhibit>95% identity
to their rat homologues. Pull-down experiments showed no interaction between GST-PDRG1
and MATβ, whereas MATα2 was able to bind to GST-PDRG1 both in the absence or presence
of the regulatory subunit (Fig 7A). However, when the MAT II oligomer was formed the
amount of MATα2 obtained by pull-down was reduced, according to the densitometric scan-
ning of the data, and no β-subunit was detected (Fig 7B). The interaction with MATα2 was fur-
ther analyzed using the truncated forms of GST-PDRG1 generated in the present study.
Similarly to MATα1 elimination of the PDRG1 C-terminal end affected the interaction
(Fig 7C), but in this case MATα2 binding was significantly reduced as deduced from data
quantification (Fig 7D).
Fig 6. Pdrg1 expression evaluated by real-time RT-PCR in rat tissues andmodels of hepatic disease.
(A) Pdrg1 expression levels in several rat tissues (N = 3), using kidney levels as reference for graphical
purposes. (B) Comparison ofMat1a (white) and Pdrg1 (black) expression levels using kidney levels as
reference for graphical purposes. (C) Changes in Pdrg1 hepatic expression at early stages of Wilson’s
disease using Long Evans Cinnamon rats 9-weeks old (LEC, N = 6) and matched control Long Evans rats
(LE, N = 5). (D) Changes in Pdrg1 hepatic expression upon D-galactosamine intoxication for 48 h (control
group N = 13, galactosamine group N = 11). (E) Pdrg1 expression differences between rat hepatoma H35
cells (N = 12) and normal livers of Wistar (W; N = 13) and LE (N = 5) rats. Histograms show the mean ± SEM
of the fold change calculated against the control group using 18s data as reference. Statistical evaluation of
the change in the animal models was performed by Students t-test against the appropriate control group
(*p0.05).
doi:10.1371/journal.pone.0161672.g006
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Interaction of PDRG1 with MATα1 alters DNAmethylation
The next question to examine was whether the PDRG1-MAT interaction affected AdoMet
production. However, the low sensitivity of the MAT activity assays and the small nuclear
level of the proteins precluded a direct evaluation of this parameter in nuclear fractions from
cell lines. Similarly, direct measurements of nuclear AdoMet levels required a long process
to eliminate the main cytoplasmic component, during which hydrolysis together with
nuclear pore exchange takes place. Therefore, the indirect approach provided by measure-
ment of global DNA methylation was preferred, together with the use of CHO cells that
allow better cotransfection levels. Mock transfected cells showed global DNA methylation
levels that depend on the AdoMet produced by MATα2 homo-oligomers and MAT II (Fig
8A). These levels were not significantly altered by HA-PDRG1 overexpression according to
the inverse radioactive assay, although a tendency towards decreased DNA methylation was
observed in all the assays performed. In contrast, FLAG-MATα1 overexpression let to DNA
hypermethylation as previously described, an effect that was precluded by coexpression with
HA-PDRG1 (Fig 8A). Altogether these data suggested a putative effect of the interaction on
MAT activity.
Fig 7. Pull-down analysis of PDRG1 interaction with MATα2 andMAT II. (A) Representative western
blots of pull-down experiments using glutathione Sepharose beads loaded with GST or GST-PDRG1 and
recombinant MATα2, MATβ or the hetero-oligomer MAT II; anti-GST, anti-MATα2 and MATβwere used for
detection. The size of the standards is indicated on the left side of the panels. (B)Quantification of the
MATα2/GST-PDRG1 signal ratio (mean ± SEM) from five independent pull-down experiments. (C)
Representative western blots of pull-down experiments carried out with the truncated PDRG1 forms and
recombinant MATα2 using anti-GST and anti-MATα2. The size of the standards is indicated on the left side of
the panels. (D)Quantification of the MATα2/GST-PDRG1 signal ratio (mean ± SEM) from five independent
pull-down experiments. All the incubations with MAT subunits or MAT II were carried out in the presence of
excess GST to avoid unspecific binding. (*p0.05 vs GST-PDRG1).
doi:10.1371/journal.pone.0161672.g007
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Interaction with PDRG1 reduced S-adenosylmethionine production by
MATs
In order to further evaluate the effects of the interaction on AdoMet synthesis by MATs, the
activity of MAT homo-oligomers was analyzed in the presence of PDRG1 in vitro (Fig 8B). For
this purpose, purified recombinant MATα1 and MATα2 homo-oligomers were obtained and
Fig 8. Effects of PDRG1 in DNAmethylation and MAT activity. (A)Global DNAmethylation levels of CHO
cells transiently transfected with pHA-PDRG1, pFLAG-MAT or both plasmids evaluated with the inverse
radioactive assay and compared to mock transfected cells. Incorporation of methyl groups into DNA
(mean ± SEM) of five independent experiments carried out in triplicate is shown. For graphical purposes, the
data are expressed as percentage of the pFLAG control taken as 100% (23392.65 ± 1790.07 cpm). Statistical
analysis was performed using GraphPad Prism and changes were considered significant when p0.05 (*vs.
pFLAG; ** vs. pHA; ***vs.FLAG-MAT). (B) Purified recombinant MATα1 (0.7 μM) was incubated with
0–5.6 μMPDRG1 (black) and S-adenosylmethionine synthesis determined; the panel shows results
(mean ± SEM) of a typical experiment out of five carried out in triplicate. Controls including MATα1 and
histone IIA (red) were also performed (C) Results (mean ± SEM) of a typical activity assay out of three
performed in triplicate using MATα2 (0.7 μM). (D) Effects of PDRG1 (mean ± SEM) on MAT II activity (0.7 μM)
from a typical experiment out of three carried out in triplicate. (E) Typical profile of a Biogel A purification of the
MATα1/GST-PDRG1 complex followed by MAT activity. Elution of the standards is indicated with sticks that
correspond to: Blue dextran (40 ml); ferritin (48 ml); aldolase (69 ml); conalbumin (81 ml); ovalbumin (84 ml);
and ATP (105 ml). The upper part of the panel shows a stained SDS-PAGE gel of the relevant fractions as
indicated on the top; the molecular size of the markers shown in the last lane (right) is indicated next to the
corresponding stained band. (F) Comparison of the MAT activity shown by the MATα1/GST-PDRG1
(MATα1-HE; top) and MATα2/GST-PDRG1 complexes (MATα2-HE; bottom) vs. MATα1 or MATα2 homo-
oligomers as correspond. The results shown are mean ± SEM of three independent experiments; *p<0.05.
doi:10.1371/journal.pone.0161672.g008
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their activity measured in the presence of increasing concentrations of PDRG1. Either type of
homo-oligomer showed up to 50% reduction in AdoMet synthesis in the presence of PDRG1
(Fig 8B and 8C). The calculated IC50 values were 3.34 ± 0.50 μM and 3.79 ± 0.48 μM for
MATα1 or MATα2 oligomers, respectively. Furthermore, PDRG1 also reduced AdoMet syn-
thesis by the MAT II hetero-oligomer obtained using purified recombinant MATα2 and
MATβ subunits (Fig 8D), the calculated IC50 value being 2.76 ± 0.22 μM in this case. Effects of
a non-related protein of a similar size such as histone IIA on MAT activity were also analyzed,
the presence of this protein having no significant effect on AdoMet synthesis by homo- or het-
ero-oligomers (Fig 8B–8D). Additionally, MATα1/GST-PDRG1 and MATα2/GST-PDRG1
complexes were prepared and purified, before MAT activity measurements (Fig 8E). Again,
decreased production of AdoMet (40–50%) by the isolated complexes was detected as com-
pared to MATα1 or MATα2 homo-oligomers (Fig 8F). Altogether these data showed a reduc-
tion of MAT activity in the presence of PDRG1.
Differential expression patterns produced by Pdrg1 silencing
Silencing of Pdrg1 expression will reduce PDRG1 levels and, in turn, decrease its possibilities
of interaction with MATs and the indirect effects observed on DNAmethylation. For this pur-
pose, rat hepatoma H35 cells were chosen given that RTqPCR results demonstrated their ele-
vated Pdrg1 levels and that nuclear accumulation of MATα1 has been described in hepatoma
cells. Therefore, H35 cells were transfected with appropriate shRNA plasmids against Pdrg1
and stable clones isolated. Among those exhibiting reproducible behavior, clones CN-10 (neg-
ative control), 3–44 (shRNA3) and 4–18 (shRNA4) were selected for further analysis. Pdrg1
expression was reduced by 50% and 70% in 3–44 and 4–18 clones, respectively, as compared
to CN-10 (Fig 9A). Crystal violet assays did not detect alterations in cell growth for any of the
stable clones, as compared to the wild type cell line (Fig 9B). RNAs of CN-10, 3–44 and 4–18
clones, as well as, RNA of an enriched pool of shRNA3 transiently transfected cells
(shRNA3T) were used for expression analysis using microarrays. Genes exhibiting changes
2-fold with FDR<0.05, according to LIMMA analysis, were identified. Pathway analysis was
performed with BioProfiling using data of 114 genes (74 upregulated and 40 downregulated)
exhibiting similar behavior in the three silenced samples (S1 Table). The consistency of their
behavior between biological replicates can be observed in the heatmap representation of the
data (S3 Fig).
Only 93 genes of the input list (81.5%), most of them among those upregulated, were rec-
ognized and classified into the following GO pathways (p<0.05): response to starvation (6;
p<0.001), lipid metabolic process (6; p = 0.01), liver development (5; p = 0.01), extracellular
space (11; p = 0–01), cytoplasm (28; p = 0.01), response to glucocorticoid stimulus (5;
p = 0.02), response to organic cyclic substance (6; p = 0.02) and extracellular region (13;
p = 0.04) (Fig 9C and S4 Fig). Selected genes, at least two of pathways with p0.02, were used
for verification of expression changes by RTqPCR, together with Pdrg1. Results were consis-
tent with those of microarrays, in general, changes being larger in clone 4–18 than in clone
3–44, as compared to the negative control CN-10 (Fig 9D). Some GO pathways identified in
microarray data were related to processes in which expression ofMat genes is altered, espe-
cially cancer development. In fact, Sema3c, Id1, Cxcl1 and Ctgf, which are upregulated in a
variety of cancer types, were downregulated upon Pdrg1 silencing. In contrast, no relevant
expression changes were detected inMat1a andMat2a during analysis of the microarray data,
and only inconsistent and modest alterations (1.5 fold) were found by RTqPCR in the stable
clones (S5 Fig). Therefore, the changes detected seem independent of alterations in the expres-
sionMat genes.
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Discussion
Remodeling of epigenetic modifications is a process that continuously takes place during the
life of an organism, in order to activate or repress the genes required for growth, the response
to different insults, etc. AdoMet is among the substrates needed by the enzymes performing
these modifications, and a reduction of its concentration is a common trait for a large variety
of pathologies [3, 5, 14]. Moreover, results derived from mouse models showing both low
(Mat1a-/-) and high (Gnmt-/-) AdoMet levels suggest the existence of a safe range of hepatic
concentrations for this metabolite to maintain normal growth [45, 46]. Thus, it is important to
know the mechanisms and actors involved in AdoMet homeostasis, which are been mainly
studied in liver. The results obtained to date using models of hepatic disease show that altered
concentrations of this metabolite commonly derive from theMat1a/Mat2a expression switch,
and post-translational modifications on cytosolic MATα1 induced by nitrosative and oxidative
Fig 9. Differential expression analysis of Pdrg1 silenced clones prepared in H35 cells. (A) Real-time
RT-PCR analysis of Pdrg1 expression using the 18s gene as reference in the stable silenced clones (3–44
and 4–18) and the negative control clone (CN-10) prepared in H35 cells. The results shown are the
mean ± SEM of four independent experiments carried out in triplicate. (B)Growth curves for H35 wild type
cells (◆), the CN-10 (■) and 4–18 (●) clones; the figure shows the mean ± SEM of eight replicates of a
representative independent experiment from the four carried out. (C) Pathway analysis of genes exhibiting
expression changes2-fold using Gene Ontology; only pathways with p<0.05 are indicated. (D) Real-time
RT-PCR verification of expression changes (mean ± SEM; N = 4) in selected genes using the Rn18s gene as
reference.
doi:10.1371/journal.pone.0161672.g009
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stress [15, 17, 21–23, 32, 47]. Identification of the interaction between PDRG1 and MATα1,
together with the reduced MAT activity exhibited by the three isoenzymes in the presence of
the former, now adds a new actor into the mechanisms that control methylation levels. In fact,
PDRG1 becomes, together with MATβ [48–50], the only two interaction targets known for
MATα1.
The reduced information available regarding PDRG1 raises doubts about where and how
the MATα1-PDRG1 interaction takes place. First, commercial Northern blots of normal
human tissues show the testis as the tissue exhibiting the highest levels of PDRG1 expression
[43]. This fact is now confirmed by RTqPCR using normal rat tissues, although similar expres-
sion levels are also detected in rat brain and cerebellum. In contrast, rat tissues exhibiting high
levels ofMat1a expression, especially the liver, but also pancreas and lung, display the lowest
expression levels for Pdrg1, a result that can be also inferred from human data [43]. Actually,
the Pdrg1 expression pattern matches that ofMat2a and seems opposite to that ofMat1a in
normal tissues [6, 51]. This observation is further reinforced by detection of increased Pdrg1
expression in D-galactosamine-treated livers, a model where elevatedMat2a expression
together with decreasedMat1amRNA levels was previously reported [17]. Second, the PDRG1
subcellular distribution is not clearly established [43, 44, 52], and hence may not match that of
MATα1. Through the use a variety of cell lines of diverse origin, confocal microscopy and sub-
cellular fractionation, we now demonstrate that PDRG1 is a nuclear and cytoplasmic protein,
although a preference for nuclear localization is detected upon quantification of the data.
These results confirm initial reports showing PDRG1 as a cytoplasmic protein [43], and also
those in which the protein is found involved in nuclear protein-protein interactions [44, 52].
Furthermore, immunoprecipitation and AGFC results demonstrate that although MATα1 and
PDRG1 colocalize in both subcellular compartments, their interaction only occurs in the
nucleus, where both proteins also colocalize with the spliceosome marker protein SC-35. Inter-
estingly, this result may be of special importance in extrahepatic tissues or in liver injury, two
situations where MATα1 localizes or accumulates into the nuclear compartment, respectively
[6, 17], thus enhancing the probability of interaction with PDRG1.
The presence of a helix-turn-helix motif and a β-prefoldin-like domain in PDRG1 were early
identified [43], and this same sequence was also recognized by PHYRE to construct a structural
model of rat PDRG1 that excludes approximately 26 residues from either end of the protein.
Characterization of recombinant PDRG1 shows its elution in a volume corresponding to a hex-
amer, an association state that has been previously attributed to prefoldins [53, 54]. The recom-
binant protein is able to interact with MATα1, leading to a larger association state according to
AGFC data. Moreover, PDRG1 is also able to interact with MATα2, as expected from the
Mat2a expression pattern and the high sequence conservation among MATα subunits [3, 4]. In
both cases, the MATα-PDRG1 interaction is altered by deletion of the C-terminal end of
PDRG1, a fact that could be anticipated since a sequence normally involved in protein-DNA or
protein-protein interactions is removed [43]. Unexpectedly, this deletion increases
MATα1-PDRG1 interaction, hence suggesting a role for the C-terminal in the control of this
binding that seems to involve the core of the predicted structure. Such an arrangement should
not interfere with the interaction site proposed for all prefoldin-like proteins (URI, Art27,
PDRG1, PFD2 and PFD6) of the R2TP/prefoldin-like complex [44, 52, 55], and that involves
the hook of the prefoldin-like domain [44]. Conversely, the fact that MATα1 andMATα2 inter-
act with PDRG1 suggests the putative involvement of a common interaction motif in the MATα
subunits, which in turn, may lay close or superimpose to the β-subunit binding site, according
to results of pull-down experiments with MAT II, where no MATβ is recovered.
MATα subunits appear as two of the few validated targets for PDRG1, together with: i)
PDCD7, a component of the U12-type spliceosome that is involved in the modulation of
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apoptosis [56]; and ii) URI and Art27/UXT, components of the prefolding complex [44](Fig
10). However, our data not only demonstrate the validity of the interaction, but also its putative
role in the control of MAT activity. PDRG1 interaction with MATα1, MATα2 or MAT II olig-
omers reduces their ability to synthesize the methyl donor, thus indicating that the interaction
takes place with their active oligomeric assemblies. Moreover, the data also suggest that in vivo
the interaction may only involve the MAT I isoenzyme and the MATα2 dimer, according to
the subcellular location of the MATα1-PDRG1 interaction (no MAT III is detected in the
nucleus) and the pull-down results for MAT II. Furthermore, MATα1 overexpression is
known to induce DNA hypermethylation in hepatoma cells [6], the preventive effect exerted
by coexpression with PDRG1 confirming the relevance of the interaction for the control of
nuclear methylations. CHO cells mainly expressMat2a andMat2b, and in this context overex-
pression of PDRG1 alone has no significant effect on DNAmethylation levels. Reasons for this
lack of effect may rely in aspects favoring a tighter MATα22-MATβ interaction or additional
interactions [10, 18], which could preclude MATα2-PDRG1 interaction and the effects on
DNAmethylation. Additionally, aberrant DNAmethylation is a well-established characteristic
of cancer cells [57], and recent studies demonstrated global DNA hypomethylation correlating
with enhanced expression of PDRG1 in a variety of human non-hepatic tumors [56, 58, 59]. In
our study, no morphological changes or apoptosis are detected upon PDRG1 overexpression,
confirming previous reports [43]. However, stable clones with partial silencing of Pdrg1 (up to
70%) show normal morphological characteristics and growth, in contrast to the severe effects
on cell growth, invasion and increased apoptosis previously described upon PDRG1 depletion
[56, 59]. This difference may rely on the use of diverse cell lines or silencing reactants and
methods. In fact, apoptosis and impairment of cell growth may be the underlying cause for the
failure to obtain stable clones with>70% downregulation of Pdrg1, regardless of the large
number of clones examined in our study. The lack of significant changes inMat1a orMat2a
expression in our silenced clones do not exclude the possibility that total suppression of Pdrg1
expression enhances MAT levels and, in turn AdoMet concentrations, known to be pro-apo-
ptotic in hepatoma cells [60].
Fig 10. Schematic representation of PDRG1 interactions. PDRG1 interactions from the literature and the
present work are presented. Arrows indicate interactions identified by a single method, bait (tail) and prey
(head). Double-headed arrows indicate interactions confirmed by several methods (solid lines) or by the
samemethod using either protein as bait (dashed lines). Proteins indicated in red have been identified in
several studies by different authors. Arrow’s color codes indicate: yeast two-hybrid (YTH; red); affinity-
purification coupled to mass spectrometry (AP-MS; violet); immunoprecipitation (IP) and YTH (black); YTH,
IP, pull-down (PD) and activity (green); AP-MS and IP (blue); PD and activity (brown).
doi:10.1371/journal.pone.0161672.g010
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Differential expression changes induced by Pdrg1 silencing are consistent between stable
clones and transient transfected pools. These modifications involve upregulation of GO path-
ways such as response to starvation, liver development, response to glucocorticoid stimulus or
lipid metabolic process. Common genes shared by these pathways include: i) Acadm that is
present in the four routes and encodes medium-chain specific acyl-CoA dehydrogenase, the
enzyme catalyzing the first step of fatty acid β-oxidation [61]; ii) Aacs, Aldob, Lipc andHmgcs2
that are shared by three of these pathways and which codify for acetoacetyl-CoA synthetase,
aldolase B, hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA synthase 2, respec-
tively; and iii) Adm that is included in two of these pathways and which encodes adrenomedul-
lin. Among them, the highest upregulation corresponds to Aldob (4–8 fold), followed by
Hmgcs2 (3–6 fold), thus suggesting a need to increase the glycolytic flux together with ketogen-
esis, which in turn provides lipid-derived energy during fasting. Additionally, genes normally
upregulated in several types of cancer cells (Sema3c, Id1, Cxcl1, Ctgf) appear downregulated by
Pdrg1 silencing [62–65]. Therefore, the changes induced in hepatoma cells by Pdrg1 downregu-
lation seem to follow an opposite pattern than those exhibited byMat1a-/- or Gnmt-/- livers
with hepatic damage (esteatosis, hepatocellular carcinoma), which show induced or normal
lipogenesis, respectively [45, 66–71]. Another characteristic of hepatocytes from these mice is
their enhanced basal proliferation [67, 68, 72], but again no change in cell growth is detected in
the Pdrg1 silenced clones. Although the lack of data about Pdrg1 expression in these mice pre-
cludes further comparison, altogether these data support a role for PDRG1 in the modulation
of changes induced by variations in AdoMet concentrations.
The nuclear localization of the MATα1-PDRG1 interaction suggests that its effects may
have special importance in that compartment, which is the preferred MATα1 site in extrahe-
patic tissues and in injured liver [6, 17]. These are two situations in whichMat1a expression is
very low or dramatically reduced, hence suggesting a specific role for PDRG1 in the control of
MAT activity by the remaining MAT I isoenzyme. Upregulated Pdrg1 expression has been
reported in UV-irradiated cell lines [43], in the presence of genotoxic agents [56] and in
human tumors [56, 58, 59]. Now we also show that this upregulation occurs in H35 cells and
acute liver injury, two conditions with different levels ofMat1a (minute or strongly reduced)
andMat2a expression (high and increased). Higher Pdrg1 expression in these two environ-
ments does not lead to significant changes in global DNA methylation [6, 17], whereas either
MATα1 overexpression or silencing of certain microRNAs induce DNA hypermethylation
and increased nuclear levels of this protein [6, 73]. In contrast, coexpression of both MATα1
and PDRG1 precluded DNA hypermethylation, hence confirming the inhibitory role of the
interaction and providing a clue to understand the lack of changes in this parameter observed
in acute liver injury. Unexpectedly, both MATα1 overexpression in H35 cells [6] and liver
injury [17] concur with increased levels of the me3K27H3 repression mark, despite the high
expression levels of Pdrg1 in these environments. A putative explanation may derive from
results on miR-214 expression in cancer, where downregulation of this microRNA inversely
correlates with Pdrg1 expression [59], and accumulation of Polycomb Ezh2 methyltransferase
is detected [74]. This methyltransferase is not only responsible of me3K27H3, but also con-
trols DNA methylation through recruitment of DNA methyltransferases in the context of
Polycomb repressive complexes 2 and 3 [75].
The possibility exists that in spite of nuclear accumulation of MATα1, the levels reached or
the amount of MAT I formed, are not enough to cope with the AdoMet requirements of the
normal cell to struggle against severe insults. In this context, oxidative stress may exert addi-
tional roles as previously hypothesized [25], among others: i) inhibiting MAT I/III [20, 24,
76]; ii) promoting anomalous subcellular distribution of MATα1 [17]; or iii) enhancing affin-
ity between MAT II subunits [10]. Through this last option oxidative stress promotes
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production of the less active isoenzyme MAT II (with the lowest Vmax), probably precluding
its interaction with PDRG1, a process that seems to require displacement of MATβ. Therefore,
under conditions in which a larger supply of AdoMet is needed to accomplish the required
epigenetic remodeling for response against an insult, interaction with PDRG1 may reduce this
provision leading to either cell death or transformation. This last consequence may be favored
by additional PDRG1 interactions involving the URI/prefoldin complex (i.e. during RNA
polymerase II assembly)[44, 52, 55, 77]. Finally, altogether the results presented in this work
made us hypothesize that the oncogenic role of PDRG1 may rely, at least in part, to its coun-
teracting effect on repression of key genes for tumor progression through interaction with
MAT I.
Supporting Information
S1 Fig. Pdrg1 expression levels in transient transfections using shRNA plasmids.H35 cells
were transiently transfected for 48 hours with shRNA plasmids harboring sequences for Pdrg1
silencing (shRNA1-4) and a negative control (CN). Transfected cells were selected for 2 weeks
with 1.8 mg/ml G418. Expression levels were analyzed by real-time RT-PCR using appropriate
primers and SybrGreen. The figure shows results of a typical experiment of the three carried
out in triplicate. Changes in Pdrg1 expression (mean ± SEM) were calculated against H35 wild
type cells and using the 18s gene as reference. Statistical evaluation was performed by one-way
ANOVA with Bonferroni post-hoc (p0.05 vs. H35;  p0.05 vs. CN).
(TIF)
S2 Fig. PDRG1 levels in hepatic nuclear fractions of D-galactosamine intoxicated rats. Sub-
cellular fractions of the whole liver from control (N = 4) and D-galactosamine (N = 6) intoxi-
cated rats were analyzed by western blotting. Lamin B1 levels were used as reference, whereas
tubulin signals were used to establish cross-contamination with cytosolic fractions. Bands with
the PDRG1 expected size (~15 kDa) were only detected in nuclear fractions upon long expo-
sure to ultrasensitive films. The size of the standards appears indicated on the left side of the
anti-PDRG1 panel. Densitometric scanning of these signals was carried out to obtain the
PDRG1/lamin B1 ratio (mean ± SEM; p 0.05).
(TIF)
S3 Fig. Graphical representation of microarray differential expression changes.Microarray
expression data were analyzed with FIESTA Viewer to identify genes exhibiting changes
2-fold with FDR<0.05. These data were used for clustering and preparation of heatmaps
using Cluster and Java TreeView, respectively. The figure shows results (N = 4) of up- and
down-regulated genes in stable clones CN-10, 3–44 and 4–18, as well as, in shRNA3T.
(PNG)
S4 Fig. Heatmaps of microarray results for relevant pathways according to BioProfiling
analysis. The figure highlights expression results of genes identified with BioProfiling
(p0.01). The pathways including these genes are: Response to starvation (GO: 0042594);
Lipid metabolic process (GO: 0006629); Liver development (GO:0001889); Extracellular space
(GO: 0005615); Cytoplasm (GO: 0005737).
(TIF)
S5 Fig. Expression ofMat genes evaluated by real-time RT-PCR in stable clones. CN-10, 3-
44-and 4–18 stable clones (N = 4) were used to analyze putative effects of Pdrg1 silencing on
Mat1a andMat2a expression using RTqPCR and appropriate TaqMan probes. The figure
shows the mean ± SEM of measurements carried out in triplicate, where expression changes
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were calculated against CN-10 and using the 18s gene as reference. Statistical evaluation was
performed by one-way ANOVA with Bonferroni post-hoc (p0.05).
(TIF)
S1 Table. Comparison of microarray results versus CN-10. The table shows expression
changes for stable clones 4–18 and 3–44 and the transient pool shRNA3T versus CN-10. Upre-
gulated genes ( 2) and downregulated genes ( -2) are listed separately.
(XLS)
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